Folate Receptor-Alpha Targeted 7x19 CAR-γδT Suppressed Triple-Negative Breast Cancer Xenograft Model in Mice

Figure 4

Antitumor ability of γδT, CAR-γδT, and 7 × 19 CAR-γδ T cells in FRa moderate expression MDA-MB-231 CDX model. (a) Tumor size comparison. Tumor xenografts were excised after treatment with different effector cells. One representative sample was displayed for each group. (b) Tumor volume curves of FRa overexpression MCF-7 CDX models. Quantification of tumor volumes (mm3) in the PBMC, γδT, CAR-γδT, 7 × 19 CAR-γδ T, and the combination of PBMC with either CAR-γδT or 7 × 19 CAR-γδT treatment groups. (c) H&E analysis of different treatment groups: (a–f) γδT, PBMC, CAR-γδT, 7 × 19 CAR-γδ t CAR-γδT + PBMC, 7 × 19 CAR-γδ T + PBMC treatment groups, respectively (40×). (d) Immunofluorescence (IF) analysis of T cells and DC cells infiltration into the tumor xenografts. (A–F) γδT, PBMC, CAR-γδT, 7 × 19 CAR-γδ T CAR-γδT + PBMC, and 7 × 19 CAR-γδ T + PBMC treatment groups, respectively (200×).

(a)

(b)

(c)

(d)